NEWS In Health Affairs: Balancing the Use of Cost-Effectiveness Analysis in Healthcare Innovations 4/14/17

A new blog post in Health Affairs by IVI's Peter Neumann and James Baumgardner addresses cost effectiveness analysis as applied across different types of of healthcare interventions, and the disproportionate emphasis placed on pharmaceuticals relative to overall healthcare spending. Neumann and Baumgardner outline some reasons why surgical CEAs are more challenging that drug CEAs, and also suggest some policy changes that can achieve greater balance, including government subsidies and payer encouragement of medical and surgical CEAs

Read more here.